Studies do not link heart risk to bone drugs: FDA

WASHINGTON (Reuters) - A review of clinical trial data from four drugmakers shows no overall risk of heart problems in patients taking drugs to treat osteoporosis, the U.S. Food and Drug Administration said on Wednesday.

The agency reviewed studies on Merck & Co's Fosamax, Roche's Boniva, Novartis AG's Reclast and Procter and Gamble Co's Actonel and found heart rhythm problems were "rare within each study, with most studies containing two or fewer events."

Still, the FDA said it was considering whether conducting further studies to investigate the risk were feasible.

The agency released its findings on its website here

(Reporting by Susan Heavey; Editing by Maureen Bavdek)